Patents Assigned to Renovo Limited
-
Publication number: 20120238505Abstract: The present invention relates to the use of a peptide, or derivative thereof of general formula X1-X2-X3-ThT-X4-LyS-X5-ATg-X6 for promoting accelerated wound healing with reduced scarring. X1 is Ala or Gly; X2 is Tyr or Phe; X3, X4 and X5 are independently selected from the group comprising Met, He, Leu and Val; and X6 is selected from the group comprising Asp, Gln and Glu.Type: ApplicationFiled: October 7, 2011Publication date: September 20, 2012Applicant: RENOVO LIMITEDInventors: Mark W.J. Ferguson, Nick Occleston, Amanda Deakin, Sharon O'Kane
-
Publication number: 20120071425Abstract: There is provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, for providing and/or maintaining a consistent skin colour, particularly to reducing redness of skin. There is also provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, as a skin improvement agent for providing a cosmetic effect and mannose-6-phosphate, or a salt, precursor or analogue thereof, for use in treating normal or damaged skin, wherein damaged skin is skin that has been subject to epidermal and/or dermal damage.Type: ApplicationFiled: June 10, 2010Publication date: March 22, 2012Applicant: RENOVO LIMITEDInventors: Mark William James Ferguson, Sharon O'Kane, Nicholas Occleston, Kerry Nield, Tracey Mason, James Bush, Julian Hanak
-
Publication number: 20110166067Abstract: The invention provides new methods of treatment using TGF-?3 to inhibit scarring in humans, and TGF-?3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-?3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-?3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-?3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-?3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.Type: ApplicationFiled: December 11, 2008Publication date: July 7, 2011Applicant: RENOVO LIMITEDInventors: Mark William James Ferguson, Sharon O'Kane, Nicholas Occleston, Nicholas Goldspink, Kerry Nield, Abdul Sattar, James Bush
-
Publication number: 20110152189Abstract: The invention provides new methods of treatment using TGF-?3 to inhibit scarring in humans, and TGF-?3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-?3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-?3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-?3 provided may be the same in each incidence of treatment. The amount of TGF-?3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-?3 may be provided by intradermal injection.Type: ApplicationFiled: December 11, 2008Publication date: June 23, 2011Applicant: RENOVO LIMITEDInventors: Mark William James Ferguson, Sharon O'Kane, Tracey Mason, Mark Cooper, Nick Occleston, David Fairlamb, James Bush
-
Patent number: 7947264Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilizing substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.Type: GrantFiled: March 12, 2007Date of Patent: May 24, 2011Assignee: Renovo LimitedInventors: Mark William James Ferguson, Phillip Mellors, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
-
Publication number: 20110105396Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Applicant: Renovo LimitedInventors: Mark William James Ferguson, Phillip Mellors, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
-
Publication number: 20110082171Abstract: Provided is the use of an agonist of a GABAA receptor for use in the prevention, reduction or inhibition of scarring formed on healing of a wound. Also provided is a method of preventing, reducing or inhibiting scarring formed on healing of a wound, in which a therapeutically effective amount of an agonist of a GABAA receptor is administered to a patient in need of such prevention, reduction or inhibition. The GABAA receptor agonist used may be an agonist specific to the GABAA receptor, such as Gaboxadol (7-tetra hydroisoxazolo[5,4-c]pyridin-3-ol), or a pharmaceutically acceptable salt thereof. The scarring to be prevented, reduced or inhibited may be scarring formed on healing of a wound of the dermis.Type: ApplicationFiled: June 2, 2009Publication date: April 7, 2011Applicant: Renovo LimitedInventors: Mark William James Ferguson, Nicholas Occleston, Sharon O'Kane, Kerry Nield, Nick Goldspink
-
Patent number: 7902150Abstract: There is provided the use of monomeric TGF-?s, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-?3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.Type: GrantFiled: March 12, 2007Date of Patent: March 8, 2011Assignee: Renovo LimitedInventors: Mark William James Ferguson, Phillip Mellors, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
-
Patent number: 7893221Abstract: The present invention concerns a method for folding a Transforming Growth Factor Beta, or a functional analogue thereof, into a dimeric, biologically active form. The method involves adding solubilized, unfolded monomeric growth factor to a solution containing 2-(cyclohexylamino)-ethanesulfonic acid (CHES) or a functional analogue thereof and a low molecular weight sulfhydryl/disulfide redox system. The solution is then incubated under conditions suitable for generating dimeric biologically active Transforming Growth Factor Beta.Type: GrantFiled: March 9, 2007Date of Patent: February 22, 2011Assignee: Renovo LimitedInventors: Mark William James Ferguson, Phillip Mellors, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Simon Higginbottom
-
Publication number: 20100184610Abstract: Provided are methods, kits and arrays for use in determining susceptibility to keloid formation. These determine susceptibility based on comparison of gene expression in a patient of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is decreased in a sample representative of gene expression in the patient compared to expression of the same gene (or genes) in the control sample this is indicative of a susceptibility to keloid formation.Type: ApplicationFiled: August 28, 2007Publication date: July 22, 2010Applicant: Renovo LimitedInventors: Mark William James Ferguson, Hugh Gerald Laverty, Nicholas Occleston, Sharon O'Kane, Darren Hodgson, Neil French, Claire Cridland, Philip Roby, Ardeshir Bayat
-
Publication number: 20100152095Abstract: A composition for use in the treatment of wounds to inhibit scar tissue formation during healing is disclosed, comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier. The method of preparation of said composition and method of administering the composition to a host suffering from tissue wounding is also disclosed.Type: ApplicationFiled: June 8, 2009Publication date: June 17, 2010Applicant: RENOVO LIMITEDInventors: Mark William James Ferguson, David Michael Foreman, Mamta Shah
-
Patent number: 7727520Abstract: The present invention provides compositions and methods for promoting the healing of wounds or fibrotic disorders with reduced scarring, comprising inhibitors and inhibiting IFN-?, together with compositions and methods for promoting the healing of chronic wounds, comprising stimulating and stimulators of IFN-?.Type: GrantFiled: July 5, 2007Date of Patent: June 1, 2010Assignee: Renovo LimitedInventor: Mark William James Ferguson
-
Patent number: 7713933Abstract: The present invention concerns stimulators of Activin and/or Inhibin for use in promoting the healing of wounds and fibrotic disorders with reduced scarring, together with medicaments and methods for promoting the healing of wounds and fibrotic disorders with reduced scarring.Type: GrantFiled: September 5, 2003Date of Patent: May 11, 2010Assignee: Renovo LimitedInventor: Mark W. J. Ferguson
-
Patent number: 7700562Abstract: The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions.Type: GrantFiled: July 23, 2003Date of Patent: April 20, 2010Assignee: Renovo LimitedInventors: Mark William James Ferguson, Georg Brunner
-
Publication number: 20100004140Abstract: Provided are methods, kits and arrays for use in determining susceptibility to keloid formation. These determine susceptibility based on comparison of gene expression in a patient of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is increased in a sample representative of gene expression in the patient compared to expression of the same gene (or genes) in the control sample this is indicative of a susceptibility to keloid formation.Type: ApplicationFiled: August 28, 2007Publication date: January 7, 2010Applicant: Renovo LimitedInventors: Mark William James Ferguson, Hugh Gerald Laverty, Nicholas Occleston, Sharon O'Kane, Darren Hodgson, Neil French, Claire Cridland, Philip Roby, Ardeshir Bayat
-
Publication number: 20090328250Abstract: Provided is a method for the expression of a TGF-? in a plant. A chimeric nucleic acid sequence comprising: (1) a first nucleic acid sequence capable of regulating the transcription in a plant cell of (2) a second nucleic acid sequence, encoding a TGF-?, and adapted for expression in the plant cell; and (3) a third nucleic acid sequence encoding a termination region functional in said plant cell is introduced into a plant cell and the plant cell grown to produce TGF-?. The nucleic acid sequence may preferably be adapted for expression in a plant chloroplast. It is preferred that the TGF-? is TGF-?3, whether full length or in the form of an active fragment.Type: ApplicationFiled: September 11, 2007Publication date: December 31, 2009Applicant: Renovo LimitedInventors: Mark William James Ferguson, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Martin Gisby, Anil Day, Phillip Mellors
-
Publication number: 20090305279Abstract: Provided are methods, kits and arrays for use in determining whether a scar of interest is keloid or non-keloid in nature. These determine keloid or non-keloid nature based on comparison of gene expression in the scar of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is decreased in a sample representative of gene expression in the scar of interest compared to expression of the same gene (or genes) in the control sample this indicates that the scar of interest comprises a keloid.Type: ApplicationFiled: August 28, 2007Publication date: December 10, 2009Applicant: Renovo LimitedInventors: Mark William James Ferguson, Hugh Gerald Laverty, Nicholas Occleston, Sharon O'Kane, Darren Hodgson, Neil French, Claire Cridland, Philip Roby, Ardeshir Bayat
-
Patent number: 7566446Abstract: Compositions for use in the treatment of wounds and fibrosis comprising a therapeutically effective amount of a compound that modulates actin assembly and organization intracellularly and/or extracellularly and a pharmaceutically acceptable vehicle; such a compound promotes the rate of wound healing and also prevents or reduces fibrosis. A preferred compound is gelsolin.Type: GrantFiled: October 2, 2006Date of Patent: July 28, 2009Assignee: Renovo LimitedInventors: Mark W. J. Ferguson, Sharon O'Kane
-
Publication number: 20090105146Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.Type: ApplicationFiled: March 12, 2007Publication date: April 23, 2009Applicant: RENOVO LIMITEDInventors: Mark William James Ferguson, Phillip Mellor, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
-
Publication number: 20080153794Abstract: The present invention relates to the manufacture of medicaments. In particular, the invention relates to the manufacture of medicaments for accelerating the healing of wounds. The invention also relates to methods of treatment for accelerating the healing of wounds. In particular the invention relates to medicaments and methods for the acceleration of healing of skin wounds.Type: ApplicationFiled: March 16, 2007Publication date: June 26, 2008Applicant: RENOVO LIMITEDInventors: Nick Occleston, Peter Hadfield, Sharon O'Kane, Mark Ferguson